Merck & Co Inc's (NYSE: MRK) investigational 15-valent pneumococcal conjugate vaccine, V114, has met its primary immunogenicity and safety endpoints in two Phase 3 pediatric programs. Full results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results